PET radiotracers for molecular imaging in dementia

Aylin Baskin, Panteleimon Giannakopoulos, Osman Ratib, Yann Seimbille, Frédéric Assal, Daniela Perani, Valentina Garibotto

Research output: Contribution to journalArticlepeer-review


Molecular imaging with various biomarkers plays a significant role in the diagnostic assessment of patients with dementing disorders, by detecting functional and pathophysiologic changes in the brain. PET imaging, in particular, allows the measurements of different molecular targets, such as functional markers of neurodegeneration (glucose metabolism), markers for pathological aggregates (such as amyloid, tau and synuclein aggregates) and neuroinflammation, and also markers of several neurotransmission systems. In the current view, neurodegenerative diseases are associated with the development of pathologic changes that play a different role in disease onset and evolution, often starting long before the onset of clinically detectable impairment. Molecular imaging represents thus a unique tool to collect relevant information contributing to accurate diagnosis, treatment and response monitoring. In this article, we review the current literature focusing on the PET radiotracers used for molecular imaging in dementia.

Original languageEnglish
Pages (from-to)215-230
Number of pages16
JournalCurrent Radiopharmaceuticals
Issue number4
Publication statusPublished - 2013


  • Amyloid
  • Biomarkers
  • Dementia
  • Glucose metabolism
  • Neurotransmission
  • Synuclein
  • Tau protein

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology


Dive into the research topics of 'PET radiotracers for molecular imaging in dementia'. Together they form a unique fingerprint.

Cite this